AvidinOX + biotinylated camptothecin

AvidinOX + biotinylated camptothecin is an experimental therapeutic system developed by Kiran Biotech for the treatment of ovarian cancer and other solid tumors. The platform utilizes **Artificial Receptor Technology (ART)**, which centers on **AvidinOX**, a chemically oxidized form of avidin. When administered locally (e.g., into the peritoneal cavity for ovarian cancer), AvidinOX acts as a tissue-bound artificial receptor by forming stable covalent Schiff base bonds with the amino groups of tissue proteins, effectively creating a long-lasting docking station. Subsequently, a biotinylated cytotoxic agent, such as **biotinylated camptothecin** or its analogues (e.g., gimatecan), is administered. Due to the extremely high affinity of biotin for avidin, the chemotherapy is captured and concentrated at the site of the AvidinOX-bound tissue. This mechanism allows for the sustained release of the drug within the tumor microenvironment, maximizing local therapeutic efficacy while significantly reducing systemic exposure and associated toxicities.

Other names

AvidinOX-biotinylated camptothecinArtificial Receptor Technology